139 related articles for article (PubMed ID: 28434114)
1. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.
Goutagny S; Giovannini M; Kalamarides M
J Neurooncol; 2017 Jun; 133(2):443-445. PubMed ID: 28434114
[No Abstract] [Full Text] [Related]
2. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
6. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract][Full Text] [Related]
7. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
Karajannis MA; Mauguen A; Maloku E; Xu Q; Dunbar EM; Plotkin SR; Yaffee A; Wang S; Roland JT; Sen C; Placantonakis DG; Golfinos JG; Allen JC; Vitanza NA; Chiriboga LA; Schneider RJ; Deng J; Neubert TA; Goldberg JD; Zagzag D; Giancotti FG; Blakeley JO
Mol Cancer Ther; 2021 Sep; 20(9):1584-1591. PubMed ID: 34224367
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
9. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
Plotkin SR; Halpin C; Blakeley JO; Slattery WH; Welling DB; Chang SM; Loeffler JS; Harris GJ; Sorensen AG; McKenna MJ; Barker FG
J Neurooncol; 2009 May; 93(1):61-77. PubMed ID: 19430883
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
[TBL] [Abstract][Full Text] [Related]
12. The molecular biology and novel treatments of vestibular schwannomas.
Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients.
Fujii M; Ichikawa M; Iwatate K; Bakhit M; Yamada M; Kuromi Y; Sato T; Sakuma J; Saito K
Neurol Med Chir (Tokyo); 2020 Feb; 60(2):75-82. PubMed ID: 31902875
[TBL] [Abstract][Full Text] [Related]
14. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
16. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
Blakeley J
Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
[TBL] [Abstract][Full Text] [Related]
17. Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis.
Shi J; Lu D; Gu R; Sun H; Yu L; Pan R; Zhang Y
Am J Otolaryngol; 2021; 42(6):103148. PubMed ID: 34214711
[TBL] [Abstract][Full Text] [Related]
18. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
